MUSC Hollings Cancer Center and Flatiron Health Partner to Deliver Advanced Cancer Care

What You Should Know:

The Medical University of South Carolina (MUSC) Hollings Cancer Center and Flatiron Health, a leading oncology-focused healthtech company, today announced a collaboration to bring Flatiron Assist™ to MUSC’s oncology care clinicians.

– The strategic collaboration equips clinicians at MUSC Hollings Cancer Center with Flatiron Assist, a unique clinical decision support platform designed specifically for oncology.  Flatiron Assist prioritizes the latest evidence-based medicine, promotes adherence to site-preferred treatment pathways, and streamlines access to relevant clinical trials – all readily available at the point of care.

Integration with Existing Systems for Seamless Workflow

Through Flatiron’s integration with MUSC’s existing Epic electronic health record system, Flatiron Assist seamlessly integrates into existing workflows. Clinicians can leverage the platform to:

  • Identify and promote site-preferred treatment pathways – These pathways represent the center’s most effective treatment approaches for various cancers.
  • Gain real-time access to open clinical trials – Patients can be efficiently matched to potentially life-saving research opportunities.
  • Ensure adherence to NCCN Guidelines – Flatiron Assist integrates seamlessly with the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®), promoting standardized and high-quality care.

“Partnering with the Medical University of South Carolina’s Hollings Cancer Center, a market-leading cancer care provider, is an incredible opportunity to accelerate our shared vision for the delivery of more standardized, efficient, and effective cancer care.” said James Hamrick, MD, Vice President of Clinical Oncology at Flatiron Health. “Flatiron Assist, tailor made for oncology, offers a clinical decision support platform that places emphasis on the latest evidence based medicine, aiming to reduce care variation while increasing access to clinical trials and novel therapies, ensuring patients at MUSC and beyond receive the highest quality of care.”